NAME: Ravi S. Suthar Department: Pharmaceutics Roll No. : NIPER0911PC14 AIM: Pegylated Solid lipid nanoparticles (pSLN) mediated targeted delivery of Vinblastine and Zosiquidar to overcome Tumour drug resistance. Introduction Development of drug resistance is a major obstacle to the success of cancer chemotherapy.
Overexpression of drug efflux transporters in tumour cells results in the development of drug resistance. Of these mechanisms, overexpression of P-glycoprotein (P-gp), a drug efflux transporter, is the most commonly encountered.PEG functionalized Solid lipid nanoparticles (pSLN) encapsulating Vinblastine and Zosiquidar can be used to overcome tumour drug resistance. Experimental Work 1) PEG functionalized Solid lipid nanoparticles (pSLN) can be prepared by a) Cold homogenization technique. b) Emulsion Evaporation Solidification method 2) Characterization of pSLN can be done using a) Particle size analysis by Photon correlation Microscopy; b) Zeta-potential determination by Zeta sizer; ) Entrapment efficiency can be calculated by Ultracentrifugation or HPLC; d) Surface analysis can be done by Transmission Electron Microscopy (TEM). 3) Cell culture study can be done to determine Vinblastine cellular uptake and accumulation in drug resistance cell.
Expected Outcomes: Inclusion of Zosiquidar along with Vinblastine in PEG functionalized Solid lipid nanoparticles (pSLN) may be resulted in significantly enhanced cellular accumulation of Vinblastine and greater cytotoxicity in drug-resistant tumour cells. * References: 1) Manthena V.S. Varma, Yasvanth Ashokraj, Dey S. Chinmoy, Panchagnula Ramesh. , 2003. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement, Pharmacological Research, 48, 347–359.
2) Breier Albert, Miroslav Barancik, Zdenka Sulova. , 2005. P-Glycoprotein Implications of Metabolism of Neoplastic Cells and Cancer Therapy. Current Cancer Drug Targets, 5, 457-468. 3) Subhashis Chakraborty, Dali Shukla, Brahmeshwar Mishra, Sanjay Singh, “Lipid – An emerging platform for oral delivery of drugs with poor bioavailability”.European Journal of Pharmaceutics and Biopharmaceutics 73 (2009) 1–15. 4) Wolfgang Mehnert, Karsten Mader, “Solid lipid nanoparticles Production, characterization and applications” Advanced Drug Delivery Reviews 47 (2001) 165–196.
5) Anna Radomska-Soukharev, “Stability of lipid excipients in solid lipid nanoparticles”. Advanced Drug Delivery Reviews 59 (2007) 411–418. 6) Rainer H. Mueller, Karsten Maeder, Sven Gohla, “Solid lipid nanoparticles (SLN) for controlled drug delivery -a review of the state of the art”. European Journal of Pharmaceutics and Biopharmaceutics 50 (2000) 161-177. ) Katja Jores, Wolfgang Mehnert, Markus Drechsler, Heike Bunjes, Christoph Johann, Karsten Mader, “Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy”.
Journal of Controlled Release 95 (2004) 217– 227. 8) Byung-Do Kim, Kun Na, Hoo-Kyun Choi, “Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan”. European Journal of Pharmaceutical Sciences 24 (2005) 199–205.